MORRISVILLE, N.C.--(BUSINESS WIRE)--Clinipace Worldwide, a global digital clinical research organization (dCRO), today announced the company has been named to Inc. Magazine’s 34th annual Inc. 500|5000 list. This prestigious list represents the most comprehensive look at America’s independent entrepreneurs.
Clinipace Worldwide was additionally named to the Inc. 5000 Honor Roll as a six-time honoree. The company reported revenue growth of 321 percent from 2011 to 2014, adding 466 jobs during that time.
“Being recognized by Inc. on a global business level for the sixth year running provides validation for our work,” commented Jeff Williams, CEO, Clinipace Worldwide. “We’re in a very competitive marketplace, and strive to continuously innovate, expand our therapeutic expertise and improve our service delivery model to stay ahead of the curve.”
This most recent recognition follows Clinipace’s announcement earlier this year of its acquisition of Accovion, a leading European full-service CRO headquartered in Frankfurt, Germany. The move strengthened the company’s operational and therapeutic expertise within Europe, and marked Clinipace’s sixth acquisition in as many years. Clinipace is now home to nearly 1,000 global staff with clinical operations and staff in 39 countries, including North and South America, Europe and Asia.
About Inc. 500|5000 List
The Inc. 500|5000 is a list of the fastest-growing private companies in the nation. Started in 1982, this prestigious list of the nation's most successful private companies has become the hallmark of entrepreneurial success. The Inc. 5000 Conference & Awards Ceremony is an annual event that celebrates their remarkable achievements. The event also offers informative workshops, celebrated keynote speakers, and evening functions. For more information on Inc. and the Inc. 5000 Conference, visit http://www.inc.com/.
About Clinipace Worldwide
Clinipace Worldwide, a digital contract research organization (dCRO), pioneered an innovative, technology-amplified CRO service model to serve the unique needs of venture-backed, mid-tier and strategic pharmaceutical, biotechnology and medical device firms.
Powered by Clinipace’s proprietary TEMPO™ eClinical platform and a team of experts with extensive knowledge in therapeutic areas such as oncology, cardiovascular, and metabolic diseases, gastroenterology, infectious diseases, nephrology, immunology and vaccines, the company assists life science firms in successfully executing regulatory strategies, clinical development and post-approval research programs.
Clinipace Worldwide global headquarters are based in Research Triangle Park, NC with additional offices located across the globe in 39 countries including North and South America, Europe and Asia. For more information, visit http://www.clinipace.com.